Abstracts tagged "methotrexate (MTX) and patient-reported outcome measures"

Abstract Number: 2486 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis
Daniel E. Furst¹, Vivian P. Bykerk², Gerd Burmester³, B Combe⁴, T W J Huizinga⁵, E Alemao⁶, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹University of California at Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Monpellier University Hospital, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Early biologic use can improve long-term control of RA,1,2 potentially leading to improved physical function and reduced pain. Recent EULAR recommendations support shared decisions…
Abstract Number: 1358 • 2013 ACR/ARHP Annual Meeting
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Roy Fleischmann¹, Alan Kivitz², Ronald F van Vollenhoven³, James W. Shaw⁴, Stefan Florentinus⁵, Piyalal M. Karunaratne⁴, Hartmut Kupper⁶, Maxime Dougados⁷ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Methotrexate (MTX) in combination with the tumor necrosis factor inhibitor adalimumab (ADA) is an effective therapy for treating rheumatoid arthritis (RA), but the minimum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].